|
Jul 16
|
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
|
|
Jun 25
|
US Equity Futures Rise Ahead of Powell Testimony
|
|
Jun 25
|
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Apr 1
|
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
|
|
Feb 24
|
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 20
|
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
|
|
Feb 19
|
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
|
|
Feb 19
|
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
|
|
Oct 4
|
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
|
|
Oct 3
|
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
|
|
Sep 30
|
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
|
|
Sep 4
|
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
|
|
Sep 3
|
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
|
|
Aug 28
|
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
|
|
Jul 29
|
Precision BioSciences to Report Second Quarter Results on August 1, 2024
|
|
Jun 20
|
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
|
|
May 13
|
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
|
|
May 7
|
Precision BioSciences to Report First Quarter Results on May 13, 2024
|